Get started
SELLAS Life Sciences Group, Inc.SELLAS Life Sciences Group, Inc.SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

SLS trade ideas

SLS OversoldSLS was sold off hard the last two days despite positive news. The current price has acted as both support and resistance in recent months (shaded area). With an RSI of 38 and the price well bellow the POC line (90 days) I think 9.08 may have been the bottom. I think the drop had more to do with large investors rebalancing for the 2nd half of the year than anything else. I would like to see the price close above the 50SMA to enter for a long swing trade. Targeting 12.89 in the short term.
NASDAQ:SLSLong
by Master_of_Fine_Charts
SLSSellas Life Sciences Group Inc (NASDAQ:SLS) After a solid breakout on rising volume SLS has pulled back to support near $9 and should set up for its next upside move. Things are now beginning to turn in favor of the Bulls. The MACD confirms the recent jump and daily RSI also shows that there's more upside to come. SLS should be watched closely, it could pay off big if it shoots up from its current level. Keep a close eye on SLS because once it does move, it should be a good one.
NASDAQ:SLSLong
by SmoothJB
Why SELLAS Life Sciences Is Surging Premarket?Why SELLAS Life Sciences Is Surging Premarket? SELLAS Life Sciences is captivating investors thanks to its late-stage cancer vaccine Thanks to some news in December in the biopharma space, SLS stock is racing higher. So what was that news? And what else do you need to know? its leading candidate Galinpepimut-S is making its way through Phase 3. This immunotherapy targets the Wilms Tumor 1, which is the leading cancer antigen. Essentially, the company believes that this therapy, which is given via vaccine, reduces the immune response in a patient and has the ability to delay the relapse of cancer. Although SELLAS Life Sciences is testing it for a variety of cancers, it is currently in Phase 3 trials for acute myeloid leukemia. This lead candidate is where the massive move in SLS stock comes from. Importantly, SELLAS Life Sciences had some big news of its own in december. While its leading immunotherapy candidate remains in clinical trials, it entered a license agreement with China-based 3D Medicines. Through this deal, 3D Medicines will handle developing and commercializing Galinpepimut-S in mainland China, Hong Kong, Taiwan and Macau. According to a company press release, this could net $202 million in license fees for SELLAS. It also could bring an upfront payment of $7.5 million sometime this quarter. it looks like another company is responsible for the move in SLS stock. What do I mean? Well, in december we saw a major rally in Greenwich LifeSciences (NASDAQ:GLSI). Ahead of a conference, the company shared promising Phase 2b data on its breast cancer immunotherapy. Importantly, Greenwich LifeSciences is evaluating GP2 as a therapy for patients who have already undergone surgery for breast cancer. And according to the report yesterday, GP2 has reduced the recurrence rate of cancer in trial participants to 0%. How does this tie into SELLAS Life Sciences? Well, GP2 and Galinpepimut-S are both unique immunotherapies that rely on vaccination as a delivery method. Essentially, both treatments are cancer vaccines. Both treatments are also quite innovative, representing potential advancements in the realm of cancer care. This means that with a more than 2,000% rally from GLSI stock, many investors may be rooting for the same with SLS. Remember though, this is a tiny company that must continue to navigate clinical trials. Keep an eye on SLS stock, but proceed with caution.
NASDAQ:SLS
by AlenCiken
Spike is not likely, but long-term looks like bullish.Great resistance at 7$, with low volume. It looks like it won't go under 7$ again for a while. SLS entered into a share purchase agreement with institutional investors! 7$ per share.Total 16.2 Million $. Once the registered direct offering is closed (yesterday or today? im not sure), I think we will see it at the 10$ level. Institutional investors get in at 7, of cousre they want to make profits. I think it will create bullish reactions. In my previous idea about SLS I wrote about a potenital spike. I don't see that coming, I see a slow but continuous uptrend. I would not be surprised if it was over 10 or 15 $ by the end of the year. These are just my own opinions. I can be wrong. Good luck.
NASDAQ:SLSLong
by OBalazs
4
Sellas Life Science Trade setupAlert set for cross above $3.00 SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutics for cancer indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Its products include galinpepimut-S and nelipepimut-S. The company was founded on April 3, 2006 and is headquartered in New York, NY.
NASDAQ:SLSLong
by DEXWireNews
$SLS TOP WATCHLIST STOCK, ON TUMOR DATAPOSITIVE DATA RELEASED ON PHASE SELLAS AnnounceS Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S. KEEP ON WATCH FOR SOME VERY POSITIVE MOVES. SHORT INTEREST 13.2% AVERAGE ANALYSTS PRICE TARGET $8.75 AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT COMPANY PROFILE SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has a Phase 3 clinical trial planned (pending funding availability) for GPS in acute myeloid leukemia (AML) and is also studying GPS in combination with pembrolizumab in multiple indications. SELLAS has received Orphan Drug designations for GPS from the FDA and the European Medicines Agency (EMA) for AML, malignant pleural mesothelioma (MPM), and multiple myeloma (MM); GPS has also received Fast Track designation for AML, MPM and MM from the FDA. SELLAS’ second product candidate, NPS, is a HER2-directed cancer immunotherapy being investigated for the prevention of the recurrence of breast cancer after standard of care treatment in the adjuvant setting. NPS has received Fast Track status designation by FDA for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following standard of care.
NASDAQ:SLSLong
by RedHotStocks